EUVIMEDOntdek EUVIMED
Crossref

Oridonin Ameliorates Alzheimer's Disease‐Like Pathology in Male Mice Through Inhibition of Receptor‐Interacting Protein Kinase 1

Yuting Li, Qingmei Cheng, Shijiao Tian, Xiaopeng Li, Yue Chen, Yujie Guo, Yunguo Jiang, Yang Tao, Xuemei Niu iD, Hong Hu iD, Yan Liu, Shenghong Li iD

Phytotherapy Research · 2026

DOI: 10.1002/ptr.70185 ↗

At a glance

Journal article in Phytotherapy Research, 2026. Written by Yuting Li and 11 co-authors. Institution: College of Medical Technology, State Key Laboratory of Southwestern Chinese Medicine Resources, the Innovative Institute of Chinese Medicine and Phar…. Major MEDLINE topics: Alzheimer Disease, Receptor-Interacting Protein Serine-Threonine Kinases, Diterpenes, Kaurane. Cited 1 times so far (Crossref); 49 references. Funded by: National Natural Science Foundation of China, National Postdoctoral Program for Innovative Talents, China Postdoctoral Science Foundation.

SamenvattingSubjectsBibliografische gegevensCiteRelated studies

Abstract (original language)

Oridonin (Ori) is a bioactive diterpenoid from Rabdosia rubescens that exhibits potent anti‐inflammatory and neuroprotective properties. However, its potential role in Alzheimer's disease (AD), especially in modulating receptor‐interacting protein kinase 1 (RIPK1)‐mediated neuroinflammation and necroptosis, remains unclear. This study aimed to investigate Ori's therapeutic mechanism in AD by targeting RIPK1. We utilized cellular thermal shift assay (CETSA), drug affinity responsive target stability assay (DARTS), and bio‐layer interferometry (BLI) to verify the binding of Ori to RIPK1. In vitro, inflammatory and necroptotic responses were assessed in BV2 microglial cells and HT22 neuronal cells using enzyme‐linked immunosorbent assay (ELISA), reverse transcription quantitative polymerase chain reaction (RT‐qPCR), Western blotting, immunofluorescence, and flow cytometry assays. In vivo, we evaluated Ori's therapeutic efficacy in 5× FAD transgenic mice, a well‐established AD model, through behavioral analysis using the Morris water maze, along with histological and biochemical assessments of brain tissues. Ori demonstrated a robust interaction with RIPK1 ( K D = 533 nM) and significantly increased its thermal and proteolytic stability. Treatment with Ori markedly suppressed the secretion of pro‐inflammatory cytokines interleukin‐6 (IL‐6) and tumor necrosis factor alpha (TNFα) in microglia by inhibiting the RIPK1–ERK1/2–NF‐κB signaling pathway. In neurons, Ori effectively blocked the activation of the RIPK1–RIPK3–MLKL signaling cascade, prevented necrosome formation, and significantly reduced necroptotic cell death. Importantly, in the 5× FAD mouse model, Ori treatment substantially improved spatial learning and memory performance, decreased amyloid‐beta (Aβ) plaque deposition, and attenuated inflammatory and necroptotic markers in both cortical and hippocampal regions. Ori as a natural small‐molecule inhibitor of RIPK1, capable of concurrently mitigating neuroinflammation and necroptosis—two critical pathological processes underpinning AD. These findings strongly support Ori's potential as a disease‐modifying therapeutic for AD.

Subjects

MeSH terms (MEDLINE)

Alzheimer DiseaseReceptor-Interacting Protein Serine-Threonine KinasesDiterpenes, KauraneAnimalsMaleMiceMice, TransgenicDisease Models, AnimalMicrogliaNeuroprotective AgentsSignal TransductionNeuronsBrainNecroptosisTumor Necrosis Factor-alphaCell Line

Author keywords

RIPK1natural productsneuroinflammationoridoninprogrammed cell death

Substances

Receptor-Interacting Protein Serine-Threonine KinasesDiterpenes, KauraneoridoninRipk1 protein, mouseNeuroprotective AgentsTumor Necrosis Factor-alpha

Authors and institutions

  • College of Medical Technology, State Key Laboratory of Southwestern Chinese Medicine Resources, the Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Chi…
  • State Key Laboratory of Phytochemistry and Natural Medicines, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China.

ORCID profiles: Xuemei Niu, Hong Hu, Shenghong Li

Funding

  • National Natural Science Foundation of China
  • National Postdoctoral Program for Innovative Talents
  • China Postdoctoral Science Foundation
  • Natural Science Foundation of Sichuan Province

Cite

APA

Li, Y., Cheng, Q., Tian, S., Li, X., Chen, Y., Guo, Y., Jiang, Y., Tao, Y., Niu, X., Hu, H., Liu, Y., & Li, S. (2026). Oridonin Ameliorates Alzheimer's Disease‐Like Pathology in Male Mice Through Inhibition of Receptor‐Interacting Protein Kinase 1. Phytotherapy Research. https://doi.org/10.1002/ptr.70185

Vancouver

Li Y, Cheng Q, Tian S, Li X, Chen Y, Guo Y, et al. Oridonin Ameliorates Alzheimer's Disease‐Like Pathology in Male Mice Through Inhibition of Receptor‐Interacting Protein Kinase 1. Phytotherapy Research. 2026. doi:10.1002/ptr.70185

BibTeX
@article{Li2026,
  author = {Li, Yuting and Cheng, Qingmei and Tian, Shijiao and Li, Xiaopeng and Chen, Yue and Guo, Yujie and Jiang, Yunguo and Tao, Yang and Niu, Xuemei and Hu, Hong and Liu, Yan and Li, Shenghong},
  title = {Oridonin Ameliorates Alzheimer's Disease‐Like Pathology in Male Mice Through Inhibition of Receptor‐Interacting Protein Kinase 1},
  journal = {Phytotherapy Research},
  year = {2026},
  doi = {10.1002/ptr.70185}
}
Start for free →